Participated · Grant · Sep 2024

Mabylon focuses on discovering and engineering human-derived, multi-specific antibodies sourced from diverse immune repertoires of allergic patients to treat allergies, neurodegenerative diseases, and inflammation. Its lead program, MY006, is a tri-specific antibody designed to neutralise peanut allergens and is being advanced toward a Phase Ia/b trial expected to complete in 2027. The company also has discovery and preclinical programs including MY010, a multi-specific cross-reactive antibody targeting birch Bet v 1 and related tree, fruit and nut allergens, and MY011 for grass pollen allergies. Mabylon says human-derived antibodies are more effective than those from animal models or artificial libraries, enabling rapid creation of high-quality antibody libraries against validated targets. The company is led by CEO Alcide Barberis and recently added Dr. Thomas Hecht to its Board of Directors, succeeding Prof. Adriano Aguzzi whose term ended in June 2025. Recent financing will fund the clinical readout for MY006 and further development of the early-stage pipeline. Mabylon develops therapeutic human-derived antibodies, with lead programs targeting peanut allergy, neurodegenerative targets (TDP-43 and APOE) and inflammasome-mediated inflammation. Its anti-allergen multispecific antibody MY006 is in IND studies and slated to enter clinical development in Q4 2025 in collaboration with Pfizer via the Pfizer Ignite program, while Mabylon retains all rights and decision-making independence. The company also collaborates with SciNeuro on TDP-43 and APOE programs, where SciNeuro holds Greater China development/commercialization rights and an option to expand worldwide; Mabylon received an upfront payment and is eligible for milestones and royalties. Recent grants (including CHF 0.8M from Innosuisse for the MY012 IBD program with the University of Zurich) and collaborations are funding preclinical proof-of-concept work. Since founding in 2015 the company has raised CHF 33.5 million in equity and non-dilutive funding and employed a team of 22 people. Mabylon is currently fundraising a Series B to advance its lead program into the clinic and another program to IND filing.